Clinical Overview
Memantine is an NMDA receptor antagonist specifically indicated for the treatment of moderate to severe Alzheimer’s disease. It represents a unique mechanism of action among dementia treatments, working by regulating glutamate activity in the brain rather than affecting cholinesterase enzymes.
Primary Clinical Applications
Memantine is indicated for moderate to severe stages of Alzheimer’s disease and may be used in combination with cholinesterase inhibitors. It helps slow cognitive decline and may improve daily functioning in patients with advanced dementia.
Mechanism and Clinical Benefits
By blocking NMDA receptors, memantine prevents excessive glutamate-mediated neuronal damage while allowing normal physiological function. This neuroprotective effect may slow disease progression and improve cognitive symptoms in moderate to severe Alzheimer’s disease.
Dosing Considerations
Memantine requires gradual dose titration over several weeks to minimize side effects and optimize tolerability. Both immediate-release and extended-release formulations are available for dosing convenience.
Prescribing Information
Dosing & Administration
Immediate Release (Namenda):
- Week 1: 5 mg once daily
- Week 2: 5 mg twice daily
- Week 3: 15 mg daily (5 mg AM, 10 mg PM)
- Week 4+: 20 mg daily (10 mg twice daily) – maintenance dose
Extended Release (Namenda XR):
- Week 1: 7 mg once daily
- Week 2: 14 mg once daily
- Week 3: 21 mg once daily
- Week 4+: 28 mg once daily – maintenance dose
Indications
- Moderate to severe dementia of the Alzheimer’s type
- May be used as monotherapy or in combination with cholinesterase inhibitors
Contraindications
- Known hypersensitivity to memantine or any component
- No absolute contraindications, but caution in severe renal impairment
Warnings & Precautions
- Renal impairment: Dose adjustment required for severe impairment (CrCl <30 mL/min)
- Genitourinary conditions: May worsen bladder outflow obstruction
- Seizure disorders: Use with caution
- Alkaline urine: May increase memantine levels
Drug Interactions
- Carbonic anhydrase inhibitors: May increase memantine levels
- Sodium bicarbonate: Alkalinizes urine, increases drug levels
- NMDA antagonists: Avoid concurrent use (amantadine, ketamine)
- Cholinesterase inhibitors: Safe combination, often used together
Adverse Reactions
Common (5-10%):
- Dizziness, headache, confusion, constipation
Less Common:
- Hypertension, vomiting, back pain, fatigue, pain
Special Populations
- Renal Impairment: Severe (CrCl <30): Maximum 10 mg twice daily (IR) or 14 mg daily (XR)
- Hepatic Impairment: No dose adjustment needed for mild-moderate impairment
- Elderly: No specific dose adjustment, but monitor for adverse effects
- Pregnancy: Limited human data; use only if potential benefits justify potential risks (PLLR labeling applies)
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
